Skip to main content

Advertisement

Table 2 Objective Response rate

From: A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)

HLA-status HLA-A*2402-matched (n = 50) HLA-A*2402-unmatched (n = 46)
Response CR PR SD PD CR PR SD PD
Number 1 30 16 3 0 28 17 1
Response rate   31/50 (62.0%)    28/46 (60.9%)